X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Verity will market TLANDO (testosterone undecanoate), the first and only oral testosterone replacement therapy in adult males indicated for conditions associated with a deficiency or absence of endogenous testosterone, in the United States and, if approved, in Canada.
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Tlando
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Lipocine
Deal Size: $270.0 million Upfront Cash: $2.5 million
Deal Type: Licensing Agreement February 02, 2024
Details:
Under the agreement, Verity Pharma will market Tlando (testosterone undecanoate), the first and only oral testosterone replacement therapy (TRT), in the United States and, if approved, in Canada.
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Tlando
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Lipocine
Deal Size: $270.0 million Upfront Cash: $2.5 million
Deal Type: Licensing Agreement January 18, 2024
Details:
Under the terms of that agreement, Cumberland acquired U.S. rights to Sancuso (Granisetron) and assumed full commercial responsibility for the product – including its distribution, marketing, promotion, manufacturing and medical support activities.
Lead Product(s): Granisetron
Therapeutic Area: Gastroenterology Product Name: Sancuso
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Cumberland Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 09, 2022
Details:
Under the terms of the agreement, Verity Pharma will promote NATESTO across the island of Puerto Rico, leveraging its existing commercial footprint and health care network. Acerus will maintain control of distribution, market access, and regulatory activities on the island of Puerto Rico.
Lead Product(s): Testosterone
Therapeutic Area: Endocrinology Product Name: Natesto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Acerus Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 10, 2022
Details:
Verity Pharmaceuticals has received a notice of compliance with conditions (NOC/c) from Health Canada for the VERITY-BCG™ (Bacillus Calmette-Guérin [BCG]: Strain Russian BCG-I).
Lead Product(s): Bacillus Calmette-Guérin: Strain Russian BCG-I
Therapeutic Area: Oncology Product Name: VERITY-BCG
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2021
Details:
The companies have entered into an exclusive agreement that grants Verity Pharmaceuticals Inc. the rights to commercialize Trelstar® (triptorelin pamoate for injectable suspension), a hormone therapy for patients living with prostate cancer.
Lead Product(s): Triptorelin Pamoate
Therapeutic Area: Oncology Product Name: Trelstar
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Debiopharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
